Skip to main content

Animations

MJFF Publications

1721 - 1730 of 8818 Results
Title
Year
  • Year
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • Summary Details
    OPEN
    Title: Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.04.032
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.05.047
    Citation Count: 18
  • Summary Details
    RESTRICTED
    Title: Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson’s disease
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neulet.2020.135443
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.04.002
    Citation Count: 46
  • Summary Details
    OPEN
    Title: The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.027
    Citation Count: 37
  • Summary Details
    RESTRICTED
    Title: Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.026
    Citation Count: 34
  • Summary Details
    OPEN
    Title: Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.07.022
    Citation Count: 16
  • Summary Details
    OPEN
    Title: GBA variation and susceptibility to multiple system atrophy
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.007
    Citation Count: 20
  • Summary Details
    OPEN
    Title: A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.029
    Citation Count: 19
  • Summary Details
    OPEN
    Title: A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.020
    Citation Count: 29
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.